A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis

202037 citationsJournal Article

Authors

Elena Morozova · First Pavlov State Medical University of St. Petersburg

Maria V. Barabanshikova · First Pavlov State Medical University of St. Petersburg

Ivan Moiseev · First Pavlov State Medical University of St. Petersburg

Alena I. Shakirova · First Pavlov State Medical University of St. Petersburg

I. Barhatov · First Pavlov State Medical University of St. Petersburg

И. Э. Ушал · Nikiforov Russian Center of Emergency and Radiation Medicine

Abstract

GVHD prophylaxis with PTCy and ruxolitinib is associated with low toxicity, good acute and chronic GVHD control, and low relapse incidence. However, the relatively high rate of SPGF should be taken into account. SPGF could possibly be mitigated by ruxolitinib dose reduction.

Topics & Keywords

Myeloproliferative Neoplasms: Diagnosis and Treatment Acute Myeloid Leukemia Research Hematopoietic Stem Cell Transplantation

Publication Details

Published in: Acta Haematologica

Volume 144, Issue 2, pp. 158-165

DOI: 10.1159/000506758

Field-Weighted Citation Impact: 2.70

Command Palette

A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis

Authors

Abstract

Topics & Keywords

Publication Details